secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2026-05-14T20:23:01+00:00
Accession:  0001104659-26-061208
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech Q1 net income $108.4M; PRV sale for $205M and ZYCUBO approval drive results
--------------------------------------------------------------------------------

- Net income $108.4M ($3.44 basic EPS) vs net loss $12.7M in Q1 2025; revenue $16.0M up from $13.1M.
- Subsidiary Cyprium sold Rare Pediatric Disease PRV for $205M in March 2026; ZYCUBO approved for Menkes disease.
- Debt reduced: prepaid Oaktree loan to $15M outstanding; cash increased to $255.8M from $79.4M.
- Checkpoint acquisition by Sun Pharma gives Fortress ~$28M upfront + 2.5% royalty on UNLOXCYT sales.
- Journey Medical's Emrosi launched; payer access expanded to 85% of US commercial lives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/0001104659-26-061208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/fbio-20260514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-061208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer